Two medicines, side by side
Guselkumab vs risankizumab
Guselkumab and risankizumab are both labeled for crohn's disease and ulcerative colitis. Pharmacies paid $14,728.91 per mL (Tremfya 100 mg/mL syringe) and $22,774.36 per mL (Skyrizi 150 mg/mL pen) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. How each works, in its label's words: Guselkumab, “Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor.”; Risankizumab, “Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
Check it at the source: the guselkumab FDA label on DailyMed (effective June 4, 2026); the risankizumab FDA label on DailyMed (effective June 15, 2026).
Highlights of the guselkumab record
Guselkumab (Tremfya) · label of June 4, 2026
Used for
From the label: indicationsTREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. […]
On the market
- Earliest approval on file
- July 13, 2017
- Generic labelers
- none listed
- Pharmacy cost
- $14,728.91 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the risankizumab record
Risankizumab (Skyrizi) · label of June 15, 2026
Used for
From the label: indicationsSKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) moderately to severely active Crohn's disease in adults. […]
On the market
- Earliest approval on file
- n/a
- Generic labelers
- none listed
- Pharmacy cost
- $22,774.36 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Guselkumab label of June 4, 2026, Risankizumab label of June 15, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do guselkumab and risankizumab differ on the record?
How each works, in its label's words: Guselkumab, “Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor.”; Risankizumab, “Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
Both are in FDA's class interleukin-23 antagonists.
Half-life, in each label's words: Guselkumab, “Mean half-life of guselkumab was approximately 15 to 18 days in subjects with plaque psoriasis across trials.”; Risankizumab, “Elimination The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day (34%) and terminal …”
| Guselkumab | Risankizumab | |
|---|---|---|
| Labeled for | Crohn's disease and ulcerative colitis | Psoriasis, Crohn's disease and ulcerative colitis |
| Pharmacologic class | Interleukin-23 Antagonist | Interleukin-23 Antagonist |
| How it works (label) | Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. | Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. |
| Half-life (label) | Mean half-life of guselkumab was approximately 15 to 18 days in subjects with plaque psoriasis across trials. | Elimination The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day (34%) and terminal elimination half-life was approximately 28 days and 21 days in subjects with plaque psoriasis and … |
| Earliest approval on file (Drugs@FDA) | July 13, 2017 | n/a |
| First generic approved | none | none |
| Generic labelers (NDC) | none listed | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $14,728.91 per mL (Tremfya 100 mg/mL syringe) | $22,774.36 per mL (Skyrizi 150 mg/mL pen) |
| 12-month price change | +5% | +6% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 35,559 | 81,290 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to guselkumab
- every medicine labeled for the same conditions